Personal Profile

Name: Liu Fanglan

Title: Associate Professor

Email: liufanglan@ncu.edu.cn

Place of Birth: Ji’an, Jiangxi Province

Supervisor Type: Master’s Supervisor

Course Taught: Clinical Pharmacology

Research Interests

Clinical Pharmacology

Tumor Pharmacology

Educational Background

(1) 2013.09–2016.06: Ph.D., Pharmacology of Traditional Chinese Medicine, Jinan University

(2) 2010.09–2013.06: M.S., Pharmacology, Jinan University

(3) 2006.09–2010.06: B.S., Pharmaceutical Engineering, Harbin University of Commerce

Work Experience

2016.07–Present: Associate Professor, School of Pharmacy, Nanchang University; Director, Department of Clinical Pharmacology Teaching and Research

Academic Services

(1) Member, Clinical Pharmacology Professional Committee, Chinese Pharmacological Society

(2) Council Member, Intelligent Decision-Making Branch of Integrated Evaluation of Traditional Chinese Medicine, Chinese Association of Traditional Chinese Medicine Informatics

(3) Council Member, Jiangxi Association of Drug Clinical Trials and Research

(4) Standing Member, Applied Pharmacology Committee, Jiangxi Pharmaceutical Association

(5) Standing Member, Medical Ethics Committee, Jiangxi Association of Drug Clinical Trials and Research

Honors and Awards

(1) 2024 – First PI of Jiangxi Higher Education Undergraduate Teaching Achievement Award (Cultivation Project)

(2) 2024 – Selected as Key Teacher Training Candidate of Jiangxi Universities

(3) 2023 – Second Prize, Jiangxi Provincial Undergraduate Teaching Achievement Award (Ranked 4th)

(4) 2022 – “Outstanding Teaching Quality Nomination Award” for the course Clinical Pharmacokinetics at Nanchang University

(5) 2022 – “Outstanding Undergraduate Class Advisor”

Major Achievements

I. Major Research Contributions

I have long focused on the mechanisms of tumor development especially breast cancer— and drug resistance, with research centered on identifying new molecular targets for cancer therapy and elucidating their mechanisms. I have presided over two National Natural Science Foundation of China (NSFC) projects and two provincial NSFC projects. In recent years, I have published 10 SCI papers as first or corresponding author in internationally renowned journals such as Molecular Cancer (IF 33.9), Cell Death & Disease (IF 9.6), Biochemical Pharmacology, and Free Radical Biology and Medicine. My work has been cited over 300 times in the past five years.

1. Research Projects (PI)

[1] NSFC Regional Science Fund (82260717): FXR-regulated ferroptosis in breast cancer invasion and metastasis (2023–2026), 340,000 RMB, Ongoing.

[2] NSFC Young Scientist Fund (81703554): Mechanism by which CAF autophagy promotes breast cancer invasion and metastasis (2018–2020), 201,000 RMB, Completed.

[3] Jiangxi Natural Science Foundation (20224BAB216117): FXR-regulated lipid peroxidation and iron overload in ferroptosis suppression in breast cancer (2023–2025), 100,000 RMB, Ongoing.

[4] Nanchang University Young Faculty Research Fund (PY201811): TGF-β1-induced CAF formation and tumor growth (2019–2021), 50,000 RMB, Completed.

[5] Jiangxi Natural Science Foundation (20242BAB25580): FXR-regulated p53 acetylation promoting ferroptosis to inhibit TNBC lung metastasis (2025–2027), 100,000 RMB, Ongoing.

[6] Industry-funded Project (HX202311220002): Safety review of nine drugs and revision of safety sections in package inserts (2024–2025), 100,000 RMB, Ongoing.

[7] MOE Industry–Education Collaboration Project (231001282155242): Online Clinical Pharmacology course development (2024–2025), 50,000 RMB, Ongoing.

[8] Jiangxi Teaching Reform Project (JXJG-22-1-42): Teaching reform of Clinical Pharmacology under medical–pharmaceutical integration (2023–2024), 10,000 RMB, Completed.

2. Representative Publications (First or Corresponding Author)

[1] Xinyue Du, Weijie Luo, Hongwu Li, Qi Gu, Ping Huang, Cheng Wang, Na Li, Fanglan Liu*（Co-corresponding author）, Chunhua Xia*. Hsa_circ_0125356 promotes gemcitabine resistance by modulating WNT canonical and non-canonical pathways via miR-582-5p/FGF9 axis in non-small cell lung cancer. Molecular Cancer（Top journal in the CAS Category 1，IF=33.9）. 2025 Feb 27;24(1):59.

[2] Ping Huang, Han Zhao, Hua Dai, Jinying Li, Xiafang Pan, Wentian Pan, Chunhua Xia*, Fanglan Liu*（Last corresponding author）. FXR deficiency induced ferroptosis via modulation of the CBP-dependent p53 acetylation to suppress breast cancer growth and metastasis. Cell Death Dis （Top journal in the CAS Category 1，IF=9.6）. 2024 Nov 14;15(11):826.

[3] Ping Huang, Han Zhao, Xiafang Pan, Jinying Li, Wentian Pan , Hua Dai, Jia Wang , Chunhua Xia and Fanglan Liu*（Sole corresponding author）. SIRT3-mediated autophagy contributes to ferroptosis-induced anticancer by inducing the formation of BECN1-SLC7A11 complex. Biochemical Pharmacology（Top journal in the CAS Category 2，IF=6.1）. 2023 Jul; 213:115592.

[4] Jia Wang, Ping Huang, Xiafang Pan, Chunhua Xia, Hong Zhang, Han Zhao, Zhao Yuan, Jianming Liu, Chao Meng and Fanglan Liu*（Sole corresponding author）. Resveratrol reverses TGF-β1 mediated invasion and metastasis of breast cancer cells via the SIRT3/AMPK/autophagy signal axis. Phytotherapy Research（CAS Q2 journal，IF=7.2）. 2023 Jan;37(1):211-230. Article DOI:10.1002/ptr.7608.

[5] Minli Huang, Mengru Fu, Jia Wang, Chunhua Xia, Hong Zhang, Yuqing Xiong, Jiake He, Jianming Liu, Bingchen Liu, Siyi Pana, Fanglan Liu*（Sole corresponding author）. TGF-β1-activated cancer-associated fibroblasts promote breast cancer invasion, metastasis and epithelial mesenchymal transition by autophagy or overexpression of FAP-α. Biochemical Pharmacology（Top journal in the CAS Category 2，IF=6.1）. June 2021; 188, 114527.

[6] Ting Lu, Bin Liao, Chao Meng, Ping Huang, Cheng Wang, Fanglan Liu*（Co-corresponding author）, Chunhua Xia*. 18β-Glycyrrhetinic acid synergizes with enzalutamide to counteract castration-resistant prostate cancer by inhibiting OATP2B1 uptake of dehydroepiandrosterone sulfate. European Journal of Pharmacology（CAS Category 2，IF=5.2）. September 2024; 983 (2024) 176995.

[7] Wen-Jun Duan# , Yi-Fang Li# , Fang-Lan Liu# （Co-first author）, Wei-Lin Yuan, Bun Tsoi, Jun-Li Chen, Qi Wang, Shao-Hui Cai, Hiroshi Kurihara, Rong-Rong He*. A SIRT3/AMPK/autophagy network orchestrates the protective effects of trans resveratrol in stressed peritoneal macrophages and RAW 264.7 macrophages. Free Radic Biol Med（Top journal in the CAS Category 2，IF=7.4）, 2016 Jun;95:230-42.

[8] Fang-Lan Liu , En-Pan Mo, Liu Yang, Jun Xu, and Shao-Hui Cai*. Autophagy is involved in TGF-β1-induced protective mechanisms and formation of cancer-associated fibroblasts phenotype in tumor microenvironment. Oncotarget, 2016 Jan 26; 7(4):4122-41.

[9] Wen-Jun Duan# , Fang-Lan Liu# （Co-first author）, Yi-Fang Li, Rong-Rong He*, Wei-Lin Yuan, Bun Tsoi and Hiroshi Kurihara. Autophagy is involved in the effects of resveratrol on prevention of splenocyte apoptosis caused by oxidative stress in restrained mice. Molecular Nutrition & Food Research（Top journal in the CAS Category 1，IF=5.3）, 2013, 57, 1145–1157.

[10] Jiawei Liu, Chao Huang, Jianming Liu, Chao Meng, Qi Gu, Xinyue Du, Minyu Yan, Yingjie Yu, Fanglan Liu（Co-author）, Chunhua Xia. Nrf2 and its dependent autophagy activation cooperatively counteract ferroptosis to alleviate acute liver injury. Pharmacol Res（Top journal in the CAS Category 1，IF=10.3）. 2023 Jan;187:106563.

3. Talent Development

（1）Supervised student Liu Yichen to win Bronze Medal at the 11th National College Student Medical Innovation Competition / Belt & Road International Competition (2025).

（2）Supervised students winning First Prize at the 15th National “Pharmacy Garden Forum” (2023).

（3）First supervisor for students winning Third Prize at the 10th National Life Sciences Competition (Jiangxi Division).

（4）Graduate student Minli Huang awarded Jiangxi Provincial Government Scholarship (2021).

（5）Graduate student Huang Ping received Excellent Paper First Prize in the “Excellence Cup” Research Innovation Competition (2023).